BiotechTube

Cenobamate

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epilepsy, Generalized

Conditions

Epilepsy, Generalized

Trial Timeline

Jul 12, 2022 → Jan 31, 2027

NCT ID
NCT06579573

About Cenobamate

Cenobamate is a phase 3 stage product being developed by Ono Pharmaceutical for Epilepsy, Generalized. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06579573. Target conditions include Epilepsy, Generalized.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT06590896Phase 2Recruiting
NCT06579573Phase 3Recruiting

Competing Products

20 competing products in Epilepsy, Generalized

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
52
LacosamideUCBPhase 3
74
Zonisamide + PlaceboEisaiPhase 3
77
ZonegranEisaiApproved
85
perampanel + perampanelEisaiPhase 1
33
Perampanel + PlaceboEisaiApproved
85
perampanelEisaiApproved
85
E2007 + PlaceboEisaiPhase 2
52
Placebo + RufinamideEisaiPhase 3
77
E2007 (perampanel) + PlaceboEisaiPhase 2
52
Perampanel Oral TabletEisaiApproved
85
perampanelEisaiPhase 3
77
PerampanelEisaiPre-clinical
23
Zonisamide + CarbamazepineEisaiPhase 3
77
PerampanelEisaiApproved
85
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
33
PerampanelEisaiPhase 2
52
Zonisamide + PlaceboEisaiPhase 3
77
zonisamide low dose group + zonisamide high dose groupEisaiApproved
85
E2007 + E2007 + PlaceboEisaiPhase 2
52

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77